FibroBiologics wins European patent for Sox9 gene therapy to regenerate cartilage

• FibroBiologics won a European patent for Sox9-based gene therapy that converts fibroblasts into cartilage-producing cells for cartilage repair.
• The grant covers expression-vector compositions delivered to fibroblasts in or for joints, using viral or non-viral delivery systems.
• The patent supports the company’s cartilage regeneration programs in orthopedics and degenerative disc disease.
• European Patent No. EP 3043825 B1 includes 12 claims, with validation planned across selected European markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA19389) on August 05, 2026, and is solely responsible for the information contained therein.